NXL · Insider Trading
Nexalin Technology, Inc. Common Stock
Every open-market purchase and sale reported by NXL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-23 | Carolyn Hamby Shelton | Sr. VP - Quality - Regulatory | A | +100,000 deriv. | — |
| 2025-12-23 | Mark White | CEO | A | +1,000,000 deriv. | — |
| 2025-12-23 | Justin Van Fleet | CFO | A | +100,000 deriv. | — |
| 2025-12-23 | Alan Kazden | Director | A | +100,000 deriv. | — |
| 2025-12-23 | David Owens | Chief Medical Officer | A | +1,000,000 deriv. | — |
| 2025-12-23 | Ben Hu | Director | A | +100,000 deriv. | — |
| 2025-09-30 | Alan Kazden | Director | A | +36,459 | — |
| 2025-09-30 | Leonard Osser | 10%+ Owner | A | +166,666 | — |
| 2025-09-30 | Ben Hu | Director | A | +36,459 | — |
| 2025-09-30 | David Owens | Chief Medical Officer | A | +36,459 | — |
| 2025-09-12 | David Owens | Chief Medical Officer | A | +303,125 deriv. | — |
| 2025-09-12 | Marilyn Elson | 10%+ Owner | Sell | −46,300 deriv. | — |
| 2025-09-12 | Carolyn Hamby Shelton | Sr. VP - Quality - Regulatory | A | +20,000 deriv. | — |
| 2025-07-21 | Leonard Osser | — | A | +600,000 deriv. | — |
| 2025-03-13 | Carolyn Hamby Shelton | Sr. VP - Quality, Regulatory | Buy | +6,000 | +$13.20K |
| 2025-02-27 | Mark White | President and CEO | A | +1,387,024 deriv. | — |
| 2025-02-27 | David Owens | Chief Medical Officer | A | +919,184 deriv. | — |
| 2025-02-05 | David Owens | Chief Medical Officer | Buy | +1,000 | +$3.10K |
| 2025-02-04 | David Owens | Chief Medical Officer | Buy | +1,000 | +$2.98K |
| 2025-01-29 | David Owens | Chief Medical Officer | Buy | +1,500 | +$4.05K |
| 2025-01-24 | David Owens | Chief Medical Officer | Buy | +3,000 | +$7.70K |
| 2024-10-30 | David Owens | Chief Medical Officer | Buy | +500 | +$1.09K |
| 2024-10-02 | Ben Hu | Director | A | +175,000 | — |
| 2024-10-02 | Marilyn Elson | 10%+ Owner | A | +1,400,000 | — |
| 2024-10-02 | Leslie Bernhard | Director | A | +49,838 | — |
| 2024-09-25 | Leonard Osser | — | A | +1,400,000 | — |
| 2024-09-25 | Leonard Osser | — | Buy | +72,000 deriv. | — |
| 2024-08-15 | David Owens | Chief Medical Officer | Buy | +1,000 | +$950 |
| 2024-07-01 | David Owens | Chief Medical Officer | Buy | +1,000 | +$1.75K |
| 2024-06-21 | David Owens | Chief Medical Officer | Buy | +1,619 | +$1.15K |
| 2024-06-12 | David Owens | Chief Medical Officer | Buy | +3,000 | +$1.92K |
| 2023-10-05 | Alan Kazden | Director | Buy | +2,500 deriv. | — |
| 2023-10-05 | Mark White | President/CEO | Buy | +25,000 deriv. | — |
| 2023-10-05 | Leonard Osser | — | Buy | +19,000 deriv. | — |
| 2023-10-05 | David Owens | Chief Medical Officer | Buy | +2,500 deriv. | — |
| 2023-06-30 | Alan Kazden | Director | Buy | +2,500 | +$10.38K |
| 2023-06-30 | Rick Morad | Director | Buy | +2,500 | +$10.38K |
| 2023-06-30 | Mark White | President/CEO | Buy | +25,000 | +$103.75K |
| 2022-09-29 | Marilyn Elson | Ms. Elson serves as CFO | Buy | +19,000 | +$21.28K |
| 2022-09-22 | Mark White | President/CEO | Buy | +25,000 | +$103.75K |
| 2022-09-20 | David Owens | Chief Medical Officer | Buy | +2,500 | +$10.38K |
| 2022-09-20 | Mark White | President/CEO | Buy | +2,500 | +$10.38K |
| 2022-09-20 | Alan Kazden | Director | Buy | +2,500 | +$10.38K |
| 2022-09-20 | Rick Morad | Director | Buy | +2,500 | +$10.38K |
| 2022-09-20 | Marilyn Elson | Ms. Elson serves as CFO | Buy | +72,000 | +$298.80K |
| 2007-04-20 | Norman Gold | Director | U | −17,153 | −$568.62K |
| 2007-04-20 | CPT Manager LTD | 10%+ Owner | J | −45,601,265 | +$877.30M |
| 2007-04-20 | Glenn J Rufrano | Chief Executive Officer | U | −498,130 | −$16.51M |
| 2007-04-20 | Matthew Goldstein | Director | U | −5,464 | −$181.15K |
| 2007-04-20 | Raymond H Bottorf | Director | U | −9,789 | −$324.52K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Marilyn Elson | Ms. Elson serves as CFO | 79,016 | $135.12K |
| Leonard Osser | 10%+ Owner | 53,953 | $92.26K |
| Ben Hu | Director | 12,570 | $21.49K |
| Mark White | CEO | 10,304 | $17.62K |
| David Owens | Chief Medical Officer | 6,375 | $10.90K |
| Alan Kazden | Director | 3,986 | $6.82K |
| Carolyn Hamby Shelton | Sr. VP - Quality - Regulatory | 1,000 | $1.71K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NXL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.